What changed
$AZN — BUY 📊 | 6 MONTHS THESIS
🎯 latest | Rev $2.7B | EPS $1.29 vs $1.27 🟢
💡 Consensus expects modest growth with peak earnings fears; we see >10% EPS CAGR supported by oncology and biologics, with positive pipeline outcomes compressing the forward P/E from 34x to ~28x as estimates rise.
📉 Reward/risk: 2.06:1
🏢 Business Quality: 8/10 - Leading oncology/immunology franchise with durable patents, strong pipeline, and double-digit growth; moderate patent-cliff risk offset by portfolio breadth.
📊 Valuation: fair — using FY2025 P/E 34x vs peer median 28x; EV/EBITDA 18x vs 15x; DCF implies $190–210 if pipeline delivers; premium justified by superior growth...
🔮 Catalyst: ASCO 2025 oral presentation of Dato-DXd Phase III data and potential Enhertu sBLA acceptance
💰 Entry: $176.43, stop $165, target $200
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/AZN0623